AR010139A1 - Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u - Google Patents

Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u

Info

Publication number
AR010139A1
AR010139A1 ARP980101481A ARP980101481A AR010139A1 AR 010139 A1 AR010139 A1 AR 010139A1 AR P980101481 A ARP980101481 A AR P980101481A AR P980101481 A ARP980101481 A AR P980101481A AR 010139 A1 AR010139 A1 AR 010139A1
Authority
AR
Argentina
Prior art keywords
molecula
antigen
dna
fas
epitope
Prior art date
Application number
ARP980101481A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of AR010139A1 publication Critical patent/AR010139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una molécula que tiene una region de union de antígeno específica para un epítope del antígeno Fas, dicho epítope se conserva entre un primate y unanimal no primate; el uso de dicha molécula para la preparacion de un medicamento, un anticuerpo, ADN que codifica cualquier porcion individual delpolipéptido de dicha molécula, un vector de ADN recombinante, una célula huésped, E-coli, un método para producir un anticuerpo anti-Fas humanizado y unagente para el tratamiento de condiciones atribuibles a anormalidades en el sistema Fas/ligando de Fas.
ARP980101481A 1997-04-01 1998-04-01 Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u AR010139A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (1)

Publication Number Publication Date
AR010139A1 true AR010139A1 (es) 2000-05-17

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101481A AR010139A1 (es) 1997-04-01 1998-04-01 Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u

Country Status (17)

Country Link
EP (1) EP0909816A1 (es)
KR (1) KR19980080993A (es)
CN (1) CN1207395A (es)
AR (1) AR010139A1 (es)
AU (1) AU734758B2 (es)
BR (1) BR9803296A (es)
CA (1) CA2233783A1 (es)
CZ (1) CZ294340B6 (es)
HU (1) HUP9800744A3 (es)
ID (1) ID20117A (es)
IL (1) IL123888A0 (es)
NO (1) NO981454L (es)
NZ (1) NZ330095A (es)
PL (1) PL325667A1 (es)
RU (1) RU2212412C2 (es)
TR (1) TR199800604A2 (es)
TW (1) TW526205B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ATE553129T1 (de) * 1998-01-23 2012-04-15 Hoffmann La Roche Antikörper gegen humanes il-12
AU4772299A (en) * 1998-06-18 2000-01-05 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
NZ515598A (en) * 1999-05-24 2004-05-28 Sankyo Co Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
EP2383290B1 (en) 2001-08-23 2019-05-08 Rsr Limited Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
TR201815885T4 (tr) 2004-01-07 2018-11-21 Novartis Vaccines & Diagnostics Inc M-csf spesifik monoklonal antikorlar ve bunların kullanımı.
WO2010013498A1 (ja) * 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503672A (ja) * 1993-10-14 1997-04-15 イミュネックス・コーポレーション Ｆａｓ拮抗剤とその利用
JPH09508009A (ja) * 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
CA2233783A1 (en) 1998-10-01
BR9803296A (pt) 2000-01-11
TR199800604A3 (tr) 1999-10-21
PL325667A1 (en) 1998-10-12
NZ330095A (en) 1998-12-23
CZ98598A3 (cs) 1998-10-14
NO981454L (no) 1998-10-02
ID20117A (id) 1998-10-01
CN1207395A (zh) 1999-02-10
HU9800744D0 (en) 1998-05-28
HUP9800744A2 (hu) 1999-02-01
TR199800604A2 (xx) 1999-10-21
IL123888A0 (en) 1998-10-30
HUP9800744A3 (en) 2001-04-28
AU734758B2 (en) 2001-06-21
CZ294340B6 (cs) 2004-12-15
NO981454D0 (no) 1998-03-31
KR19980080993A (ko) 1998-11-25
TW526205B (en) 2003-04-01
RU2212412C2 (ru) 2003-09-20
EP0909816A1 (en) 1999-04-21
AU5970198A (en) 1998-10-08

Similar Documents

Publication Publication Date Title
AR012035A1 (es) Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR010139A1 (es) Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
CR6538A (es) Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
CL2008003323A1 (es) Uso de un anticuerpo que se une a cd20 porque sirve para preparar un medicamento para tratar enfermedades autoinmunes; acido nucleico que codifica una proteina cd20 de mono cynomolgus; vector que lo comprende; celula huesped y polipeptido cd20 de mono cynomolgus (div.sol.no.2639-03).
DE69535719D1 (de) Fas-antigenbindender ligand
ES543938A0 (es) Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis.
FI945221A0 (fi) Yhdistelmä-DNA-molekyylejä, jotka koodittavat aminopeptidaasientsyymejä, ja niiden käyttö rokotteiden valmistamiseksi matotartuntoja vastaan
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
UY27499A1 (es) Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular
NO20010412L (no) Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine
ATE296312T1 (de) Metalkomplexbildner
DK0500659T3 (da) Monoklonale antistoffer.
GB2278357B (en) Humanised antibodies directed against A33 antigen
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
NO980743L (no) Antisekretoriske faktorpeptider som regulerer patologiske permeabilitetsforandringer
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure